Phase 3 trial suggests benefit of MDMA‐assisted therapy for PTSD
The Brown University Psychopharmacology Update August 1, 2021 Peer reviewed DOI: 10.1002/pu.30752
Summary
Adding MDMA to therapy for PTSD significantly improved symptoms and reduced functional impairment compared to a placebo. There was no increase in adverse events, including suicidality, associated with MDMA use.
Study at a glance
| Design | Phase 3 trial |
|---|---|
| Population | individuals with post-traumatic stress disorder (PTSD) |
| Key finding | MDMA combined with therapy led to significant symptom improvement and reduced functional impairment compared to placebo. |
Abstract
Adding 3,4‐methylenedioxymethamphetamine (MDMA) to manualized therapy for post‐traumatic stress disorder (PTSD) resulted in significant symptom improvement and reduced functional impairment relative to placebo in a Phase 3 trial. The researchers observed no increase in adverse events from use of MDMA, including no increase in suicidality. Study results were published online May 10 in Nature Medicine.